Erythropoietin promotes hepatic regeneration after extended liver resection in rats

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 7 PT1, 2008, Pages 1125-1131

  Schmeding, Maximilian ^a   Boas Knoop, Sabine ^a   Lippert, Steffen ^a   Ruehl, Martin ^b   Somasundaram, Radjan ^b   Dagdelen, Tarkan ^b   Neuhaus, Peter ^a   Neumann, Ulf P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Gastroenterology and Hepatology Campus Benjamin Franklin Universitaetsmedizin ^*  (Germany)

Author keywords

Erythropoietin (EPO); Hepatic regeneration; Liver resection

Indexed keywords

CYCLINE; HYPOXIA INDUCIBLE FACTOR 1; KI 67 ANTIGEN; MESSENGER RNA; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER REGENERATION; LIVER RESECTION; MALE; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; SURVIVAL;

EID: 47649094187     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05265.x     Document Type: Article

References (35)

1. Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl Acad. Sci. USA 2004 101 : 4477.
2. am Esch JS 2nd, Knoefel WT, Klein M et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 2005 23 : 463.
3. Yokoyama Y, Nagino M, Nimura Y. Mechanisms of hepatic regeneration following portal vein embolization and partial hepatectomy: a review. World J. Surg. 2007 31 : 367.
4. Novelli G, Rossi M, Pretagostini R et al. A 3-year experience with Molecular Adsorbent Recirculating System (MARS): our results on 63 patients with hepatic failure and color Doppler US evaluation of cerebral perfusion. Liver Int. 2003 23 (Suppl. 3 10.
5. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin. Liver Dis. 2001 21 : 105.
6. Pawlik TM, Poon RT, Abdalla EK et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch. Surg. 2005 140 : 450.
7. Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol. Dial. Transplant. 1999 14 (Suppl. 2 22.
8. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004 9 (Suppl. 5 18.
9. Arnoletti JP, Brodsky J. Reduction of transfusion requirements during major hepatic resection for metastatic disease. Surgery 1999 125 : 166.
10. Lentschener C, Gomola A, Grabar S et al. The effect of erythropoietin on allogeneic blood requirement in patients undergoing elective liver resection: a model simulation. Anesth. Analg. 2004 98 : 921.
11. Abdelrahman M, Sharples EJ, McDonald MC et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004 22 : 63.
12. Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl Acad. Sci. USA 2004 101 : 14907.
13. Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res. Cardiol. 2005 100 : 397.
14. Calvillo L, Latini R, Kajstura J et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl Acad. Sci. USA 2003 100 : 4802.
15. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002 106 : 2973.
16. Chong ZZ, Kang JQ, Maiese K. Erythropoietin: cytoprotection in vascular and neuronal cells. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2003 3 : 141.
17. Schmeding M, Neumann UP, Boas-Knoop S, Spinelli A, Neuhaus P. Erythropoietin reduces ischemia-reperfusion injury in the rat liver. Eur. Surg. Res. 2007 39 : 189.
18. Sepodes B, Maio R, Pinto R et al. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl. Int. 2006 19 : 919.
19. Glanemann M, Munchow S, Schirmeier A et al. Steroid administration before partial hepatectomy with temporary inflow occlusion does not influence cyclin D1 and Ki-67 related liver regeneration. Langenbecks Arch. Surg. 2004 389 : 380.
20. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987 162 : 156.
21. Campbell JS, Prichard L, Schaper F et al. Expression of suppressors of cytokine signaling during liver regeneration. J. Clin. Invest. 2001 107 : 1285.
22. Brooling JT, Campbell JS, Mitchell C, Yeoh GC, Fausto N. Differential regulation of rodent hepatocyte and oval cell proliferation by interferon gamma. Hepatology 2005 41 : 906.
23. Ferrario E, Ferrari L, Bidoli P et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat. Rev. 2004 30 : 563.
24. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. (Maywood) 2003 228 : 1.
25. Grasso G, Sfacteria A, Cerami A, Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go? Neuroscientist 2004 10 : 93.
26. Grasso G, Sfacteria A, Passalacqua M et al. Erythropoietin and erythropoietin receptor expression after experimental spinal cord injury encourages therapy by exogenous erythropoietin. Neurosurgery 2005 56 : 821.
27. Grimm C, Wenzel A, Groszer M et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat. Med. 2002 8 : 718.
28. Kadri Z, Petitfrere E, Boudot C et al. Erythropoietin induction of tissue inhibitors of metalloproteinase-1 expression and secretion is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways. Cell Growth Differ. 2000 11 : 573.
29. Uchida N, Leung FY, Eaves CJ. Liver and marrow of adult mdr-1a/1b (-/-) mice show normal generation, function, and multi-tissue trafficking of primitive hematopoietic cells. Exp. Hematol. 2002 30 : 862.
30. Wulf GG, Luo KL, Jackson KA, Brenner MK, Goodell MA. Cells of the hepatic side population contribute to liver regeneration and can be replenished with bone marrow stem cells. Haematologica 2003 88 : 368.
31. Alison MR, Poulsom R, Jeffery R et al. Hepatocytes from non-hepatic adult stem cells. Nature 2000 406 : 257.
32. Takehara T, Tatsumi T, Suzuki T et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004 127 : 1189.
33. Yoshida K, Matsuzaki K, Mori S et al. Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am. J. Pathol. 2005 166 : 1029.
34. Stephanou A. Role of STAT-1 and STAT-3 in ischaemia/reperfusion injury. J. Cell Mol. Med. 2004 8 : 519.
35. Haga S, Ogawa W, Inoue H et al. Compensatory recovery of liver mass by Akt-mediated hepatocellular hypertrophy in liver-specific STAT3-deficient mice. J. Hepatol. 2005 43 : 799 807.